トロンボキサンA_2受容体拮抗薬(ラマトロバン : バイナス^<【○!R】>錠)の薬理学特性と臨床効果  [in Japanese] Ramatroban (Baynas^<【○!R】>) : a review of its pharmacological and clinical profile  [in Japanese]

Access this Article

Author(s)

Abstract

ラマトロバン(バイナス<SUP>®</SUP>錠)は, トロンボキサンA<SUB>2</SUB> (TXA<SUB>2</SUB>)受容体拮抗薬であり本邦における臨床試験においてその有用性が証明され, 2000年に承認されたアレルギー性鼻炎治療薬である. 本剤は, 通常成人にはラマトロバンとして1回75mgを1日2回経口投与する. 本剤は血小板凝集抑制作用を有するため, 出血傾向のある患者には慎重に投与, 高齢者には, 低用量(100mg/日)から投与を開始するなど患者の状態を観察しながら慎重に投与する. また, 本剤の血中動態は食事の影響をほとんど受けない.

Bayer has been interested in the observations that metabolites of arachidonic acid are involved in allergy and inflammation. Ramatroban was thus developed as a therapeutic agent for allergic and inflammatory diseases. Ramatroban showed an antagonistic action on the thromboxane A<SUB>2</SUB> (TXA<SUB>2</SUB>) receptor in in vitro experiments using platelets or arteries. It inhibited the permeability of capillary and also the infiltration of eosinophils in nasal mucosa. Ramatroban had an inhibitory effect on the nasal resistance stimulated by either U-46619 or antigen challenge in in vivo experiments. The concentration of nasal TXA<SUB>2</SUB> was increased when the antigen was challenged to allergic patients. Clinical trials demonstrated that ramatroban decreased sneezing, rhinorrhea, and rhinostenosis in patients enrolled in the study. No serious adverse reaction of ramatroban was observed in patients throughout the trials. The treatment with ramatroban is safe and improves nasal symptoms.

Journal

  • Folia Pharmacologica Japonica

    Folia Pharmacologica Japonica 118(6), 397-402, 2001-12-01

    The Japanese Pharmacological Society

References:  16

Codes

  • NII Article ID (NAID)
    10008181513
  • NII NACSIS-CAT ID (NCID)
    AN00198335
  • Text Lang
    JPN
  • Article Type
    REV
  • ISSN
    00155691
  • NDL Article ID
    5995120
  • NDL Source Classification
    ZS51(科学技術--薬学)
  • NDL Call No.
    Z19-247
  • Data Source
    CJP  NDL  J-STAGE 
Page Top